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Abstract
Aim To compare the frequency and factors associated with diabetes medication-taking (depression, perceived side
effects, self-efficacy and social support) in people with mild to moderate intellectual disability and those without
intellectual disability.
Methods In stage 1 of this study, we collated information on diabetes medication-taking and associated factors in 111
people with diabetes: 33 adults with mild to moderate intellectual disability and 78 adults without intellectual disability.
Validated instruments measuring medicine-taking, self efficacy, depressive symptoms, perceived level of social support
and perceived side effects were administered in both groups. In stage 2, we used an abductive qualitative approach to
triangulate stage 1 findings with carers responses (n = 12).
Results The instruments showed good internal reliability (Cronbach’s a = 0.7–0.9). Comparisons between people with
intellectual disabilities and those without revealed similar frequency of medication-taking (70% vs 62%; P = 0.41).
People with intellectual disabilities and diabetes had significantly higher depressive symptoms, as measured by
the Glasgow Depression Scale for people with a Learning Disability (P = 0.04), higher levels of perceived side effects (P
= 0.01), and lower confidence levels, as measured by the Perceived Confidence Scale (P = 0.01). The results of stage 2
showed how carers of people with intellectual disabilities and diabetes optimized medication-taking yet infrequently
discussed the side effects of medicines.
Conclusions Further investigation of medication-taking and side effects may result in the development of an evidence-
informed intervention to improve medicines safety in people with intellectual disabilities.
Diabet. Med. 00, 1–9 (2020)
Introduction
Globally, the WHO has suggested that improving adherence
to medicines may have a greater impact on chronic disease
management than any other scientific advancements [1].
Medication adherence occurs when the patient’s actions
match the prescribed regimen, with optimum adherence
achieved when medicines are taken as prescribed 80–95%
of the time [2]. Adherence maximizes therapeutic effect,
improves quality of life, alleviates clinical symptoms and
minimizes adverse drug events. Despite these benefits, it is
estimated that up to 50% of medicines are not taken as
prescribed [1], and medication-taking in people with
diabetes is amongst the poorest [2]. Comparing diabetes
to hypertension and asthma, diabetes medication-taking
was estimated at 66% [3]. Furthermore, a systematic review
of 45 studies concluded that non-adherence to diabetes
medication was one of the most common reasons for
hospitalization [4], and significant correlations between
non-adherence to medication and poor glycaemic control
are evident [5]. The long-term consequences of poor
glycaemic control include hypoglycaemia or hypergly-
caemia, cardiovascular disease, limb amputation, renal
and visual impairment, and premature death [6]. Thus,
medication-taking is a crucial factor in optimizing health in
people with diabetes.
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Bandura’s social cognitive theory [9] conceptualizes the
complexity of medication-taking as an interwoven process
between cognitive, psychological and environmental factors.
Psychological well-being, confidence or self-efficacy, medi-
cation beliefs and level of social support play an important
role in mediating whether or not people with diabetes take
their medicines [7–10]. A systematic review and meta-
analysis of 47 independent samples demonstrated that
depression had a moderate effect on treatment and medica-
tion-taking in people with type 1 and type 2 diabetes [7].
Moreover, a meta-analysis of 48 studies concluded that,
when measured against depression, low self-efficacy may be a
more significant indicator of poor medication-taking than
depressive symptoms [8]. Perceptions of medication side
effects have a significant impact on health-related quality of
life and medication adherence [9]. Environmental factors
(such as social support) may also influence medication-
taking. A mixed-methods study [13] found that presence of
social networks was a strong predictor of diabetes medica-
tion adherence in people with diabetes, a finding corrobo-
rated by Gherman et al. [8].
Whilst social cognitive theory has provided some clarity on
factors associated with medication-taking in the general pop-
ulation with diabetes, it not known how those factors translate
to people with intellectual disabilities and diabetes. Adults with
intellectual disabilities are two to three times more likely to
develop diabetes [11] and to have suboptimal glycaemic control
[12]. Given the cognitive impairments, communication diffi-
culties, greater reliance on family or paid carers and lack of
engagement with primary healthcare professionals [13] in this
population, it is hypothesized that such individuals are at
greater risk of suboptimal medication-taking.
The aim of the present study was to apply social cognitive
theory in a prospective mixed-methods study to investigate
the key characteristics, depressive symptoms, self-efficacy,
perceived side effects and social support with regard to
diabetes medication-taking in adults with diabetes with and
without intellectual disabilities.
Methods
We conducted a two-stage mixed-methods study comparing
and contrasting adults with type 1 or 2 diabetes with and
without intellectual disability, who were taking prescribed
diabetes medication, in a single health board in Scotland. The
study was completed in November 2017.
Stage 1
Participants
The target sample size was 109 and was derived from a power
analysis using G*Power 3.1.5 with a = 0.05 and power = 0.80,
and assuming an estimated effect size of f2 = 0.15. Information
about the studywasdistributed to regionalgeneralpractices (n=
124), diabetes outpatient clinics (n = 2), a diabetic clinical
research facility (n = 1), specialist community intellectual
disability services (n = 3) and a social care department (n = 1).
The named informants were two general practitioners, three
diabetes research nurses and three intellectual disability spe-
cialists. During the recruitment phase, potential participants
were approached via the named informants, then contacted by
the researcher and, if eligible, recruited to the study. Eligible
participants were aged >18 years, able to provide voluntary
consent, diagnosed with type 1 or 2 diabetes and prescribed
glucose-lowering medicines. Intellectual disability was defined
according to the International Classification of Diseases (ICD)-
10 which categorizes intellectual disability as borderline, mild,
moderate, severe and profound [14]. Given that in previous
research classification of intellectual disability was rarely
formally documented [15] and given the absence of a regional
database, a pragmatic approach to identification of participants
was adopted. This involved named informants identifying
people with mild to moderate intellectual disability and
diabetes, corroborating the results with medical records and
verifying diagnosis during recruitment.
Data collection
Demographic, dependent and independent variable data,
numbers and types of prescribed diabetes medication, and
insulin vs glucose-lowering agent data, were self-reported
and these reports were corroborated with a medicines chart
or repeat prescription information. Diabetes medication was
defined as any prescribed first-, second- or third-line glucose-
lowering agents [17]. HbA1c data were extracted from
electronic medical records and the value reported within 6
months of the interview was recorded. Demographic data
recorded were: age; level of intellectual disability; diabetes
duration; level of education; living situation; prescribed
medicines; and whether or not the participant was receiving
insulin therapy.
Measurements. The five validated instruments described
below were used to collate data from participants with
diabetes with and without intellectual disability.
What’s new?
• Approximately 30–50% of medicines are not taken as
prescribed, with a paucity of research on medication-
taking specific to people with intellectual disability.
• The frequency of medication-taking in adults with
diabetes with and without intellectual disabilities is
similar. People with intellectual disabilities and diabetes
had perceived side effects to be greater compared to
people without intellectual disabilities and diabetes.
• People with intellectual disabilities and diabetes may
benefit from increased pharmacovigilance and screening
for side effects by family, paid carers and healthcare
professionals.
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1. Medication adherence was measured using the self-re-
ported, eight-item Morisky Medication Adherence Scale
(MMAS-8) [16]. This instrument asks the participant to
state ‘yes’ or ‘no’ to a series of questions, and one point is
received for each answer aligned to the expected response.
Scores of ≥6 are defined as good adherence, and scores <6
as poor adherence. Results were corroborated with HbA1c
values, and suboptimal diabetes control was defined as
HbA1c >58 mmol/mol (>7.5%) [17].
2. Depressive symptoms were measured using the Glasgow
Depression Scale for people with a Learning Disability
(GDS-LD), a 20-item scale which has been psychometri-
cally tested for use in adults with mild to moderate
intellectual disability [18]. In the present study a score of
≥10 indicated depressive symptoms.
3. Self-efficacy was measured using the four-item Perceived
Competence in Diabetes Scale (PCS). For each of the four
components, perceived competence is rated on a scale of 1
(not at all true) to 7 (very true) and the score is
transformed to a scale 0 to 100. Higher score indicates
greater self-efficacy [19].
4. The Perceived Sensitivity to Medicines scale (PSM) [20] is
a short five-item instrument. Individual item scores are
summed to provide a total PSM score ranging from 5 to
25. Higher scores indicate greater perceived medicine side
effects.
5. Perceived level of social support was assessed using the
eight-item modified Medical Outcomes Study Social Sup-
port survey (mMOS-SS) [21]. Participants rate items
across a five-point Likert scale, and the score is totalled
and transformed to a scale of 0–100. The higher the score
the greater the perceived level of social support.
With the exception of the GDS-LD, the instruments had
not previously been used or validated in adults with
intellectual disabilities. To optimize comprehension of items
in the instruments, minor linguistic modifications and further
explanation using illustrations from Boardmaker, were
made. Boardmaker is a software package of standardized
picture symbols commonly used with people who are strong
visual learners, which includes people with intellectual
disabilities. The amended scales were reviewed for compre-
hension and time needed to complete by people with
intellectual disability and intellectual disability clinicians.
All instruments were completed within an hour, with
minimal support from the researcher.
Data analysis. Data were analysed using SPSS 22 statistical
package. Cronbach’s a measured the reliability of instru-
ments, with a score of 0.7–1.0 demonstrating good internal
reliability. Comparisons of medication-taking, demographic
data and factors previously associated with adherence were
made between the intellectual disability and non-intellectual
disability groups using the chi-squared test (for binary data)
and the Mann–Whitney U-test for data measured on the
ordinal scale (as these data had outliers and were considered
non-normal). Statistical significance was determined at the
5% level. No allowance was made for the multiplicity of
tests. There was no imputation of missing data.
Stage 2
Participants
In stage 2, qualitative semi-structured interviews were
conducted with a sample of family and paid carers of stage
1 participants. The primary research question of interest was
whether the frequency of, and factors associated with,
medication-taking were consistent with the views of carers
supporting diabetes medication-taking in stage 1 partici-
pants? Thus, the aim was to triangulate stage 1 findings and
explore enablers and barriers to medication-taking. Carers
were eligible to participate if they had supported stage 1
participants with medication-taking for more than 1 year and
they agreed to participation. The target number of carer
participants was between 10 and 15.
Table 1 Topic guide for stage 2 interviews
Introduction.1. Can you just tell me what relationship (if
any) you are to this person?
2. How do you help them take their diabetic medicines?
3. Part of the study was to look at how well the patient felt
they took their medication, can you give me some
information about how you believe (participant’s name)
takes their medicine.
4. What do you see as the barriers to (participants name)
taking medicines and what do you see as the things that
help (him or her) to take insulin and/or oral medicines?
5. Can you talk a bit about how you think mood affects how
well they take their medicine,
6. Does this affect how you support him or her taking
medications?
7. Can you tell me a bit about how confident he or she feels
in managing his or her medication?
8. Do you feel confident in supporting him or her managing
treatment – if yes why? /if no why?
9. We asked whether worries about side effects from the
medications or whether they felt the medications are doing
them any good. Can you talk a bit about whether you
think has any worries about side effects or whether they
feel the medicines help them control their diabetes?
10. Do you have any views about the diabetes medicines that
your patient takes (insulin or pills)? Side effects/do they
work?
11. We asked service users what they thought about their
level of social support, what is your impression of how
this impacts on taking their diabetic medicines.
12. There are three main parts to diabetes self care: 1)
medicines; 2) exercise; 3) diet. In your view what do you
think is the most challenging for Stage 1 participant? Can
you explain to me why that is?
ª 2020 The Authors.
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Methods
Following preliminary analysis of stage 1 data, a topic guide
was designed and used in the semi-structured interviews in
stage 2 (Table 1). To ensure that carers’ views reflected their
own perspective of stage 1 participants’ medication-taking,
results relating to the person they cared for were not
discussed. On completion, data were matched to the respec-
tive stage 1 participant results, integrated and aligned.
Data analysis
Interviews were digitally recorded, transcribed verbatim and
analysedusingNVIVO software. Stage 1 and2datawerematched
and analysed to create an in-depth explanation and verification
of stage 1 results. An abductive, six-stage-approach thematic
analysiswas then conducted. This involved familiarizationwith
the data by reading them, listening to audio recordings, coding
and categorizing them into relevant data extracts and, where
necessary verifyingmeaningwith research participants. Themes
were then created from meaningful patterns in the data, and
aligned to stage 1 data. These themes were then checked by a
second qualitative researcher with the original dataset. Validity
and robustness of themes were confirmed when both research-
ers (R.P., L.H.) agreed themes and verified that they were
coherent, consistent and distinctive.
Study ethics
Ethical approval for the study was granted by the Integrated
ResearchApproval System (IRASno14-NS-0060),Health Service
and University committees in the region. All study participants,
provided informed written consent prior to study enrollment.
Results
Stage 1
Sample characteristics
Of 164 invited participants, 50 (31%) were people with
intellectual disability. A total of 111 participants (68%)
were included in the analysis: 33 (30%) in the intellectual
disability group and 78 (70%) in the non-intellectual
disability group. All datasets were complete and instru-
ments showed good internal reliability (Table 2; Cron-
bach’s a = 0.7–0.9). Demographic characteristics (Table 3)
showed that 81% of participants had a diabetes duration
of >6 years, and 75% had a diagnosis of type 2 diabetes.
Comparisons between the intellectual disability and non-
intellectual disability groups showed that the male:female
ratio was similar, and the intellectual disability group had
a lower median age (51 vs 64 years; P = 0.05) and a lower
level of secondary school education (P = 0.008). A higher
proportion of the intellectual disability group was
employed (45% vs 3%; P = 0.001), lived alone (52% vs
23%; P = 0.005) and received support with medicines
(70% vs 5%; P = 0.05). A lower proportion of the
intellectual disability group with type 2 diabetes was
prescribed insulin (11% vs 57%; P = 0.05). The intellec-
tual disability group had a significantly higher median
GDS-LD depression score (11 vs 8; P = 0.04), higher PSM
scores (side effects; 14 vs 11; P = 0.01) and lower median
PCS (self-efficacy) scores (75 vs 93; P = 0.01). Perceived
levels of social support were similar in both groups.
Comparisons of frequency of medication adherence in
intellectual disability and non-intellectual disability groups
Table 4 shows the frequency of medication adherence data,
as measured by the MMAS-8. A higher proportion of the
intellectual disability group reported good or excellent
adherence (MMAS-8 score ≥6) compared to the non-
intellectual disability group (70% vs 62%, respectively).
There was no statistically significant difference in glycaemic
control (P = 0.82), frequency of adherence (P = 0.41) or
mean adherence score (P = 0.65) across the two groups.
According to the MMAS-8, the most common reason for
non-adherence was ‘forgetting’ in the group overall, and the
second most common reason in the intellectual disability
group was because ‘medicines made them feel worse’ (18%
vs 8%; P = 0.17), which was corroborated by the overall
Table 2 Internal reliability of dependent (eight-item Morisky Medication Adherence Scale) and independent (depression, medication side effects,
self-efficacy and social support) measurement instruments
Scale
Group
overall
Diabetes and intellectual disability
group, Cronbach’s a
Diabetes without intellectual disability
group, Cronbach’s a
Medication adherence (MMAS-8;
eight-item scale)
0.7 0.7 0.7
Depression (GDS-LD; 20-item scale) 0.8 0.8 0.8
Medication side effects (PSM; five-
item scale)
0.9 0.8 0.9
Self-Efficacy (PCS; four-item scale) 0.9 0.9 0.9
Social support (mMOS-SS; eight-
item scale)
0.9 0.9 0.9
GDS-LD, Glasgow Depression Scale for people with a Learning Disability; MMAS-8, eight-item Morisky Medication Adherence Scale;
mMOS-SS, modified Medical Outcomes Study Social Support Survey; PCS, Perceived Competence in Diabetes Scale; PSM, Perceived
Sensitivity to Medicines.
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higher median PSM scores (14 vs 10) in people with
intellectual disability (Table 5).
Stage 2
In stage 2, all eligible carers (n = 27) were contacted by letter
and invited to participate. Of those, eight declined, four were
uncontactable and three did not attend the scheduled
interview. Thus, an opportunistic sample of 12 carers
comprising nine with intellectual disability and three without
intellectual disability was obtained. Interviews were 15–35
min in duration. In the intellectual disability group, four
were paid carers and five unpaid. In people without intellec-
tual disability, all were family members. With regard to
triangulation, stage 1 and 2 results were aligned to medica-
tion adherence and depressive symptoms, but not perceptions
of side effects. Thematic analysis of the data identified two
main themes: 1) optimization and 2) barriers. Samples of
coding and definitions of themes are outlined in Table 6.
Triangulation
Eleven carers’ reports of medication-taking were matched
with stage 1 participant reports, and carers across the
intellectual disability and non-intellectual disability sample
Table 4 Comparison of dependent variables (medicines adherence and HbA1c) in the group overall, and in people with and without intellectual
disability
Variable
Group
overall,
N = 111
Diabetes and intellectual disability, n =
33
Diabetes without intellectual
disability,
n = 78 P
Suboptimal glycaemic control*, n
(%)
67 (60) 18 (55) 49 (63) 0.42†
Median HbA1c, mmol/mol 61 60 61 0.82
‡
MMAS-8 ≥6 (good adherence),
(%)
71 (63) 23 (70) 48 (62) 0.41†
Mean (SD) medicines adherence
score
6.4 (1.7) 6.5 (1.6) 6.3 (1.7) 0.65§
MMAS-8, eight-item Morisky Medication Adherence Scale.
*HbA1c >58 mmol/mol (7.5%). MMAS-8 score ≥6.
†Chi-squared test for significance (ordinal variable).
‡Non-parametric Mann–Whitney U-test as outliers detected in continuous data.
§Independent t-test as parametric continuous data.
Table 3 Descriptive statistics of the group overall and comparisons between people with diabetes with and without intellectual disability
Socio demographics
Group
overall,
N = 111
Diabetes and intellectual
disability,
n = 33
Diabetes without intellectual
disability,
n = 78 P
Median age, years 62 51 64 0.05*
Intellectual disability, n (%) 33 (30) - -
Women, n (%) 55 (50) 15 (45) 40 (51) 0.58‡
Lower than secondary school education level, n (%) 82 (74) 30 (91) 52 (66) 0.008*
Employed, n (%) 17 (15) 15 (45) 2 (3) 0.001*
Living alone, n (%) 35 (31) 17 (51) 18 (23) 0.003*
Type 2 diabetes, n (%) 83 (75) 27 (82) 56 (72) 0.266‡
Type 1 diabetes, n (%) 28 (25) 6 (18) 22 (28) 0.266‡
Prescribed insulin, n (%) 63 (57) 9 (27) 54 (69) 0.05*
Type 2 diabetes prescribed insulin , n (%) 35 (42) 3 (11) 32 (57) 0.05*
Support with diabetes medications, n (%) 27 (24) 23 (70) 4 (5) 0.05*
>4 medicines prescribed, n (%) 93 (84) 28 (85) 65 (83) 0.84‡
Diabetes >6 years, n (%) 90 (81) 24 (73) 66 (85) 0.14‡
Median (IQR) GDS-LD score 8 11 (5–16) 8 (5–10.2) 0.04*
Median (IQR) PSM score 11 14 (10–17) 11 (8–14) 0.01*
Median (IQR) self-efficacy (PCS) score 93 75 (57 -93) 93 (83–100) 0.01*
Median (IQR) perceived level of social support
(mMOS-SS) score
85 78 (67–96) 88 (75–100) 0.09†
GDS-LD, Glasgow Depression Scale for people with a Learning Disability; IQR, interquartile range; mMOS-SS, modified Medical Outcomes
Study Social Support Survey; PCS, Perceived Competence in Diabetes Scale; PSM, Perceived Sensitivity to Medicines.
*Statistically significant difference between the group with diabetes and intellectual disability and the group with diabetes without intellectual
disability.
†Non-parametric Mann–Whitney U-test as outliers detected continuous data.
‡Chi squared test for significance (ordinal variable).
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reported that those with MMAS-8 scores ≥6 used medica-
tions as prescribed (response: ‘fine’) and that they were ‘used
to it’. Others with sub-optimal adherence and poor gly-
caemic control reported that participants were frequently
‘distracted’ or ‘forgetful’. One paid carer of a participant
with intellectual disability reported:
‘. . .. if something comes up, he’s very good at going away
and not taking his insulin stuff with him’ (MMAS-8 score
5, HbA1c 100 mmol/mol).
Carers of people with intellectual disability and diabetes
perceived a link between mood and medication-taking.
Those with elevated depression scores (GDS-LD score >10)
reported a negative relationship between depressive symp-
toms and medication-taking, mitigated by the support
offered by the carer.
‘. . .if she’s depressed, I think she’d just say, "Well, I’m not
taking it, there’s no point’. I quite firmly believe that.’
(GDS-LD score 12, MMAS-8 score 8, HbA1c 46 mmol/
mol)
A paid carer of a participant with intellectual disability
reported how low mood manifested in a reluctance to take
medications, which was overcome with persuasion, resulting
in high MMAS-8 scores:
‘. . .if her mood is low. . . if something has happened she’s
reluctant to take her medication. But then, she always will
come around and she will take it.’ (GDS-LD score 21,
MMAS-8 score 8)
Theme 1: Optimization
Carers of participants adopted a dynamic and proportionate
approach to optimizing medication-taking, such as ‘remind-
ing’, ‘persuading’ and ‘physical support’. This proportional-
ity was evident across all medicines regimens. For example,
when a participant with intellectual disability and type 2
diabetes required insulin therapy, care shifted from self-
Table 5 Frequency and chi-squared comparisons of unfavourable responses to the eight-item Morisky Medication Adherence Scale questionnaire in
the group overall, intellectual disability and non intellectual disability groups
Morisky MMAS-8 adherence scale (favourable answer*)
Group
overall,
N =
111
Diabetes and
intellectual
disability, n = 33
Diabetes without
intellectual
disability,
n = 78
Chi
squared
test
P value
1. Do you sometimes forget to take your diabetes medication? (N) 51 (46) 12 (36) 39 (50) 0.19
2. Over the past 2 weeks, were there any days when you did not take
your diabetes medication? (N)
27 (24) 7 (21) 20 (26) 0.62
3 Have you ever cut back or stopped taking your diabetes medication
without telling your doctor because you felt worse when you took
it? (N)
12 (10) 6 (18) 6 (8) 0.17‡
4 When you travel, or leave home, do you sometimes forget to bring
along your diabetes medications? (N)
18 (16) 1 (3) 17 (22) 0.02†
5 Did you take your diabetes medication yesterday? (Y) 3 (3) 0 (0) 3 (4) 0.55
6 When you feel like your diabetes is under control, do you sometimes
stop taking your medications? (N)
3 (3) 2 (6) 1 (1) 0.21‡
7 Do you ever feel hassled about sticking to your diabetes treatment
plan (N)
26 (23) 11 (33) 15 (19) 0.11
8 How often do you have difficulty remembering to take all your
diabetes medications (never, sometimes, always)
43 (39) 12 (36) 31 (40) 0.73
MMAS-8, eight-item Morisky Medication Adherence Scale.
*Possible responses: yes/no; correct response = 1 point; incorrect response = 0 points. Possible responses: never (1 point); almost never,
sometimes, quite often, always (0 points). Possible scale range = 0–8. Poor adherence: MMAS-8 score <6; medium adherence: MMAS-8 score
6 and 7; good adherence MMAS-8 score = 8.
†Statistically significant, P < 0.05.
‡Expected count <5 so exact test was selected for Pearson’s chi-square.
Table 6 Themes and definitions from stage 2 data analysis
Theme Theme descriptor
1. Optimization Optimization strategies were defined as any type of psychological or physical assistance which the carer interpreted as
support for the person with or without intellectual disability in taking prescribed diabetes medicines. Prescribed
diabetes medication was defined as a pharmacological treatment regimen recommended by a prescriber or other
healthcare professional (e.g. diabetes specialist nurses, district nurse or pharmacist) designed to optimize glycaemic
control
2. Barriers How carers of individuals with or without intellectual disability interpreted the influence that depression side effects,
self-efficacy and social support had on adherence of the participants in stage 1 to their prescribed diabetes medicines
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management to the carer and healthcare professional. A
needle phobia resulted in insulin injections being managed by
the carer and district nurse:
‘. . .it took us about a year. . .there is always a staff
member in with him when the nurses come in to give him
his injections because he requested it, so yeah that’s what
we did.’ (MMAS-8 score 8, HbA1c 102 mmol/mol).
In another case, a paid carer’s account of supporting a
person with intellectual disability and type 2 diabetes
included attempts to give full autonomy when managing
medicines. However, support shifted back to carers following
accidental overdose:
‘When she had her medication in a cabinet in her bedroom,
she opened it and she took an overdose of her medication,
so that’s why we hold onto it. . .. we hand her the blister
pack and she always knows which day, which time it is.’
Ongoing attempts by the carer to shift self-management to
the person with intellectual disability were also evident:
‘We’ve been starting to get her to count how many she has
each time as well, so she knows in the afternoon there’s
three tablets, so she knows that, she knows which ones, so
she’s getting to knowwhat she’s taking andwhat time she’s
taking them at.’ (MMAS-8 score 8, HbA1c 46 mmol/mol).
Theme 2: Barriers
A barrier to medication-taking in the majority of cases was
side effects not being discussed, with half of carers not aware
of perceived side effects even when high PSM and low
MMAS-8 scores were reported. A family carer of a person
with intellectual disability and diabetes, lacked insights into
the side effects of metformin..
‘. . ...he’s been on the metformin for a year/18 months
maybe. . .. I think he realises they are doing him good-
. . .cause if he doesn’t take them his blood sugar is sky
high.’ (PSM score 22, MMAS-8 score 5)
In a minority of cases (n = 3) common side effects were
reported by carers of people with an intellectual disability
and, if sufficiently intolerable, medicines were reviewed and
PSM scores lowered.
‘. . .. he was having diarrhoea. . .and we took that infor-
mation back to the doctor and obviously, they changed his
medication.’ (PSM score 9, MMAS-8 score 8).
This suggests that, infrequently, carers of people with
intellectual disability and diabetes took appropriate action by
shifting care back to the healthcare professional for a review
of medications.
Discussion
As far as the authors are aware, this is the first study to
compare the characteristics of diabetes medication-taking in
adults with and without intellectual disability and has
provided a preliminary insight into the frequency of medi-
cation-taking and associated factors in this vulnerable group
living with diabetes.
The findings suggest that people with intellectual disability
and diabetes have similar rates of medication-taking to those
without intellectual disability. This finding was corroborated
in stage 2 when carers of people with intellectual disability
optimized medication-taking using verbal reminders, persua-
sion and professional support. Moreover, carers were cog-
nisant of the impact that depressive symptoms had on
medication-taking, with those with high levels of anxiety or
depression having support increased. Although the link
between mood and adherence has been inferred previously
in the intellectual disability literature [22], this is the first
study to describe how carers facilitate medication-taking in
people with depressive symptoms and intellectual disability.
Carer support may explain similar rates of medication-taking
in the two groups, and frequency of adherence is similar to
previous published research [3], but continues to fall short of
recommended rates of optimum adherence [2]. Thus, there is
a need for further research to establish effective person-
centred, evidence-based interventions targeted at optimizing
medication-taking in people with intellectual disabilities and
diabetes. One area that may warrant further investigation is
the impact of side effects on medication-taking in people
with intellectual disability.
In the present study in people with intellectual disability
and diabetes, the PSM scores were higher and, in responses
to the MMAS-8, reports of feeling worse after taking
medicines in were noted. Associations between side effects
and medication-taking have previously been reported in
people with diabetes [9], but evidence of the influence in
people with intellectual disability and diabetes is novel.
Comparing number of medicines prescribed in the intellec-
tual disability group with that in the non-intellectual
disability group revealed no difference, suggesting type,
rather than number, account for higher PSM scores in people
with intellectual disability and diabetes. Significantly fewer
people with intellectual disability and type 2 diabetes were
prescribed insulin. As an alternative they were prescribed
oral hypoglycaemic medication, known to have significant
gastric side effects [23] and a negative impact on medication-
taking [9]. That said, insulin treatment carries the risk of
hypoglycaemia, a serious, potentially fatal and avoidable
complication of diabetes [24] and links between hypogly-
caemia, cognitive impairment and dementia have also been
reported [25]. Furthermore, a qualitative study of 29
healthcare providers caring for people with intellectual
disability and diabetes expressed concern about hypogly-
caemia and effective support for insulin management, citing
them as barriers to commencing insulin in people with
intellectual disability [26]. Intensifying treatment from twice-
daily oral therapy to a minimum of three-times-daily insulin
therapy may also affect a person’s quality of life as a result of
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increased support, loss of independence and confidence [27].
Therefore, the lower rates of insulin-prescribing in people
with intellectual disability and type 2 diabetes may be a
pragmatic choice made with people with intellectual disabil-
ities.
Although well-meaning, decisions not to prescribe insulin
may reduce the opportunity for optimum glycaemic control,
increasing risk of long-term diabetes complications in people
with intellectual disabilities [28]. The present study suggests
that, with support, people with intellectual disability and
diabetes may achieve similar rates of medication-taking to
those without intellectual disability. Given the higher rates of
hospitalization, shorter life expectancy and poorer overall
health among people with intellectual disability [29], it may
be advisable to discuss the suitability of insulin therapy with
these individuals and their carers. Although the sample size
was small, the mismatch between people with intellectual
disability reporting high perceived side effects and carers’
limited awareness of side effects warrants further explo-
ration. Raising awareness in the carer population of phar-
macovigilance and the consequences of side effects of
diabetes medication-taking may increase prescriber-led
medicines review, treatment and dose adjustments. This
may reduce perceived side effects and improve medication-
taking in people with intellectual disability and diabetes.
The present study has some important limitations, which
affect the generalizability of its findings. Identifying eligible
participants to attain a sufficiently powered sample of people
with intellectual disability was challenging. We attribute this
to recruiting from a single health service area, the absence of
a database identifying people with intellectual disability and
diabetes, and the need for named informants to identify
potential participants. Underpowered studies in vulnerable
groups are common, and a recent systematic review of 53
studies reported a median sample size of 48 participants with
cognitive impairment and only 26% of studies met their
target sample size [30]. To optimize participation from
people with intellectual disabilities, significant investment is
required for multicentre studies, longer recruitment phases
and additional resources to support carer and gatekeeper co-
participation. A second limitation was the heterogeneous
study population which limited between-group comparisons
and generalizability. Age and employment differences
between people with and without intellectual disability
may have been mitigated by utilising case–control method-
ology. Additionally, recruiting equal numbers of people with
and without intellectual disability is a consideration for
future research design. Finally, sequencing of stages may also
be considered a limitation; however, the chosen mixed-
methods design, quantitative before qualitative, obtained an
unbiased view of medication-taking. Reversing the stages
may have resulted in carers reflecting on their behaviour and
adjusting how they supported medication-taking, thus skew-
ing quantitative results.
Despite these limitations, this study is important as it
provides new insights into the similarities and differences in
medication-taking in people with and without intellectual
disability. A further study with a larger sample, longer
recruitment period and case–control design, focusing on the
predictive value of side effects and medication-taking in
people with intellectual disability and diabetes is recom-
mended. In the interim, clinician-led interventions and
regular medicines review, with emphasis on exploring side
effects, may develop a greater shared understanding between
the prescriber, carer and person with intellectual disabilities
relating to the risks, benefits and treatment alternatives. This
may improve medication-taking and glycaemic control and
reduce morbidity and mortality in people with intellectual
disability and diabetes.
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